Decades of Work in PHC

Development Sciences has a two-decade legacy in driving and delivering personalized healthcare, impacting the early and late clinical development pipelines and changing the way our organization approaches drug development. Learn more about about how DevSci has shaped Personalized Healthcare over the past 20 years:

  • Approved Drug
  • Pipeline Success
  • Failure/Lesson Learned
  • Organizational
  • PHC Innovation

Transforming Healthcare

The work we are doing today has remarkable potential to improve and save the lives of patients throughout the world. Take a look at what we are doing today to change the future of tomorrow:

infographic

Circulating Tumor DNA (ctDNA)

healthcare icon
infographic

Minimal Residual Disease (MRD)

healthcare icon
infographic

Blood Tumor Mutational Burden (bTMB)

healthcare icon
infographic

Immunogenicity

healthcare icon
infographic

Tumor Agnostic Treatment

healthcare icon
infographic

Blood-based Biomarker for Alzheimer’s (AD)

healthcare icon
arrow

DevSci for COVID-19

Since the beginning of the pandemic, DevSci has worked at unprecedented speed to help patients and communities fight COVID-19. Check out a few highlights of those efforts:

Safety Assessment

Safety Assessment

Learn about SA’s involvement in reviewing clinical protocols, authoring regulatory documents and providing scientific feedback to support multiple COVID-19 related trials
Bioanalytical Sciences (BAS)

Bioanalytical Sciences (BAS)

Find out more about BAS’ work on the Actemra study and how their biomarker work will help other programs targeting COVID-19
DevSci Informatics (DSI)

DevSci Informatics (DSI)

Discover how DSI is collaborating with OMNI-BD, PHC Floodlight and pREDi to conduct an analysis into MS data collected in CONSONANCE during the COVID-19 pandemic
Clinical Pharmacology (ClinPharm)

Clinical Pharmacology (ClinPharm)

Find out how ClinPharm continued to support programs virtually and how they adapted to mitigate the impact of COVID-19 on our medicines.
OMNI Biomarker Development (OMNI-BD)

OMNI Biomarker Development (OMNI-BD)

Discover how OMNI-BD is driving the COVASTIL biomarker efforts and supporting three molecules across four COVID-19 trials
Business Management and Communications (BM&C)

Business Management and Communications (BM&C)

Learn more about how BM&C led efforts to understand the implications and impact COVID-19 has had to our vendors and to determine if decision-making data would be impacted
arrow

DevSci: Advancing Science Through Innovation

Beyond the Bench

Beyond the Bench

DevSci remains committed to discovering and utilizing new technologies and approaches to drug development to further PHC and improve patient’s lives around the world.

More
SAfety Biomarker Expert Resource (SABER)

SAfety Biomarker Expert Resource (SABER)

Find out how this cross-functional group of biomarker experts across the entire organization are helping drive personalized healthcare

More
arrow

Dosing Strategies and Personalized Healthcare

Our medicines are administered to patients at the right dose and at the right schedule, via the optimal route of administration. Learn more about the various dosing strategies DevSci applies to fit the individual needs of patients around the world.

Providing Patients Flexibility and Convenience

Providing Patients Flexibility and Convenience

right-arrow
Precision (Individualized) Dosing

Precision (Individualized) Dosing

right-arrow
arrow

The Quest to Cure MS

Learn more about how the entire Genentech/Roche organization is working to find a cure for Multiple Sclerosis

Digital
Data
Clinical & Patient
Reported Data
Imaging
Data
Genetics & Functional
Genomics
Biomarker
Data
Advanced
Analytics

The Latest on PHC in DevSci

Check out the latest news on PHC efforts happening with DevSci.

OBD News

Newsletter | December 2018

Learn more about OBD’s 2019 PHC efforts and activities, including using biomarkers to increase PTS of molecules, accelerating clinical development programs and differentiating our molecules from our competitors.

arrow

OBD: At the Crossroads of Personalized Medicine

DNA News | November 2018

Learn more about our OBD organization and how they are at the center of our pipeline’s personalized medicine capabilities

arrow

Blood-based tumor mutational burden as a predictor of clinical benefit in NSCLC patients treated with atezolizumab

Nature Medicine | August 2018

Paper announcing results from a retrospective analysis of the OAK and POPLAR studies that stem from our collaboration with Foundation medicine

arrow
Close Bitnami banner
Bitnami